- The efficacy of gliflozins (sodium-glucose cotransporter-2 inhibitors) in patients with type 2 diabetes (T2D) is unchanged by age and not dependent on concomitant statin use.
Why this matters
- Clinical data on the effects of glucose-lowering drugs on cardiovascular events in the elderly are limited.
- Avoidance of medications that may cause hypoglycemia is advised in elderly populations.
- Meta-analysis of data from 3 industry-sponsored cardiovascular outcome trials of gliflozins and 2 subanalyses, involving 34,323 patients with T2D of whom 49.8% were age ≥65 years and 75.3% were taking statins.
- Funding: “Associazione Salute con Stile” and “PreVenENDO.”
- HRs for major adverse cardiovascular events (MACE):
- 0.95 (95% CI, 0.86-1.05) for
- 0.83 (0.71-0.96) for ≥65 years (P=.15).
- HRs for MACE:
- 0.87 (95% CI, 0.81-0.94) for those taking a statin vs
- 0.88 (95% CI, 0.77-1.01) for those not taking a statin (P=.90).
- Meta-analysis limitations.